Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
NYSE:RCUS
Price:
15.5 USD
-2.52%
Market Closed
Updated:
Jun 10, 2024
Arcus Biosciences Inc
Total Liabilities & Equity
|
Arcus Biosciences Inc
Total Liabilities & Equity Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Total Liabilities & Equity
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$148.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$56.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$93B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$23.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$34.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
27%
|
See Also
What is Arcus Biosciences Inc's Total Liabilities & Equity?
Total Liabilities & Equity
1.3B
USD
1.3B
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Total Liabilities & Equity amounts to 1.3B USD.
What is Arcus Biosciences Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
38%
38%
Over the last year, the Total Liabilities & Equity growth was 3%. The average annual Total Liabilities & Equity growth rates for Arcus Biosciences Inc have been 11% over the past three years , 38% over the past five years .
You don't have any saved screeners yet
